A study found that treatment with HEPZATO KIT showed a promising response rate of 36.3% for patients with unresectable metastatic uveal melanoma.
Clinical Trials
TIL Therapy Promising in Uveal Melanoma, Tool Predicts Responders
A type of therapy that involves “liberating” T cells from a suppressive tumor environment showed promise in the treatment of patients with uveal melanoma.
SCIB1 Plus Nivolumab/Ipilimumab Generates ORR of 85% in Advanced Unresectable Melanoma
SCIB1 plus nivolumab and ipilimumab elicited responses in patients with advanced, unresectable melanoma
Uveal Melanoma Immunogenomic Score Shows Predictive Potential
Investigators have developed a Uveal Melanoma Immunogenomic Score (UMIS) to predict which patients with metastatic uveal melanoma will respond to immunotherapy, according to findings published in Nature Communications.